CN102026655A - 脂笼蛋白-2作为心脏和中风风险的预后和诊断标记 - Google Patents

脂笼蛋白-2作为心脏和中风风险的预后和诊断标记 Download PDF

Info

Publication number
CN102026655A
CN102026655A CN2009801160607A CN200980116060A CN102026655A CN 102026655 A CN102026655 A CN 102026655A CN 2009801160607 A CN2009801160607 A CN 2009801160607A CN 200980116060 A CN200980116060 A CN 200980116060A CN 102026655 A CN102026655 A CN 102026655A
Authority
CN
China
Prior art keywords
ngal
level
risk
medicine
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801160607A
Other languages
English (en)
Chinese (zh)
Inventor
徐爱民
汪玉
R·任能博
G·W·H·高德礼
陈佩儿
M·莱曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R & C Biogenius Ltd
Versitech Ltd
Original Assignee
R & C Biogenius Ltd
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R & C Biogenius Ltd, Versitech Ltd filed Critical R & C Biogenius Ltd
Publication of CN102026655A publication Critical patent/CN102026655A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801160607A 2008-04-30 2009-04-16 脂笼蛋白-2作为心脏和中风风险的预后和诊断标记 Pending CN102026655A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/113,056 US8030097B2 (en) 2008-04-30 2008-04-30 Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
US12/113056 2008-04-30
PCT/CN2009/000405 WO2009132510A1 (en) 2008-04-30 2009-04-16 Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks

Publications (1)

Publication Number Publication Date
CN102026655A true CN102026655A (zh) 2011-04-20

Family

ID=41254765

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801160607A Pending CN102026655A (zh) 2008-04-30 2009-04-16 脂笼蛋白-2作为心脏和中风风险的预后和诊断标记

Country Status (5)

Country Link
US (1) US8030097B2 (https=)
EP (1) EP2300048A4 (https=)
JP (1) JP5687186B2 (https=)
CN (1) CN102026655A (https=)
WO (1) WO2009132510A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103959060A (zh) * 2011-09-30 2014-07-30 私募蛋白质体公司 心血管危险事件预测及其用途
CN110325106A (zh) * 2017-02-20 2019-10-11 加利福尼亚大学董事会 无症状性脑缺血的血清学测定

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
US20120219561A1 (en) * 2009-07-31 2012-08-30 Ingeneron, Inc. Prophylaxis Against Cancer Metastasis
CA2780301A1 (en) 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
US20110269150A1 (en) * 2010-02-10 2011-11-03 Cleveland Heart Lab Compositions and methods for predicting cardiovascular events
US8383580B2 (en) 2010-06-10 2013-02-26 The Regents Of The University Of Michigan Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
WO2012042061A1 (en) * 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
US9533041B2 (en) * 2010-12-03 2017-01-03 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of heart failure
CA2827511A1 (en) * 2011-02-22 2012-08-30 Innavirvax A method for the prognosis of progression of the hiv disease
US9212361B2 (en) 2012-04-19 2015-12-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of hypertension
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
US9594083B2 (en) * 2012-09-28 2017-03-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for the treatment of cardiovascular fibrosis
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
KR102443523B1 (ko) * 2020-11-24 2022-09-15 경상국립대학교산학협력단 리포칼린-2 단백질을 이용한 발작에 의한 뇌신경세포 사멸 예측 또는 진단을 위한 정보제공방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2381551T3 (es) * 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Marcadores de riesgo para enfermedad cardiovascular
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
CN101010001A (zh) * 2004-05-06 2007-08-01 哥伦比亚大学受托人 Ngal用于减少和改善局部缺血和肾中毒损伤
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
WO2006084142A2 (en) * 2005-02-04 2006-08-10 The Scripps Research Institute Dyslipoproteinemia associated with venous thrombosis
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP2062054A1 (en) * 2006-09-05 2009-05-27 Beth Israel Deaconess Medical Center, Inc. Use of lipocalin 2 in the regulation of insulin sensitivity
KR100819122B1 (ko) * 2006-09-30 2008-04-04 남명진 췌장암 진단용 키트
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP2095106B1 (en) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103959060A (zh) * 2011-09-30 2014-07-30 私募蛋白质体公司 心血管危险事件预测及其用途
CN110325106A (zh) * 2017-02-20 2019-10-11 加利福尼亚大学董事会 无症状性脑缺血的血清学测定

Also Published As

Publication number Publication date
US20090274709A1 (en) 2009-11-05
US8030097B2 (en) 2011-10-04
JP2011519037A (ja) 2011-06-30
WO2009132510A1 (en) 2009-11-05
EP2300048A1 (en) 2011-03-30
EP2300048A4 (en) 2011-08-24
JP5687186B2 (ja) 2015-03-18

Similar Documents

Publication Publication Date Title
US8030097B2 (en) Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
JP2011519037A5 (https=)
KR101245877B1 (ko) Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
WO2007103568A2 (en) Methods and compositions for the diagnosis of diseases of the aorta
EP1888765A2 (en) Methods and compositions for the diagnosis of venous thromboembolic disease
US8632990B2 (en) Detection of soluble adiponectin receptor peptides and use in diagnosis and therapeutics
JP5419968B2 (ja) 心臓治療を必要とする個体におけるｌ−ｆａｂｐ、ナトリウム利尿ペプチド及び心筋トロポニン
EP2095106A2 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
EP2376919B1 (en) Combined natriuretic peptide assays
US8163504B2 (en) Combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
CN103370619A (zh) 诊断或风险预测心力衰竭的方法和试剂
JP2020034564A (ja) 心不全リスクの予測改善のためのバイオマーカー
CA3052349A1 (en) Proadm as marker indicating an adverse event
JP2019523889A (ja) インスリン様増殖因子結合タンパク質７およびメタロプロテアーゼ２の組織阻害剤を使用する急性腎臓傷害の管理
US9347959B2 (en) Oxidative biomarkers in predicting risk of stroke, transient ischemic attack (TIA) and peripheral arterial disease (PAD)
JP2012502290A (ja) メタボリックシンドロームを有する患者におけるナトリウム利尿ペプチドおよびアディポネクチン
US20110059540A1 (en) Identifying susceptibility of a subject to cardiac therapy based on determination of a cardiac troponin, scd40l, and c-reactive protein
EP2533653B1 (en) Homoarginine as a biomarker for the risk of mortality
US8383355B2 (en) Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
EP2766732B1 (en) Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure
EP3438669A1 (en) Method for determining susceptibility to diabetes
EP2385372A1 (en) Kidney disease in normal and abnormal pregnancy
HK1229887A1 (en) Means and methods for assessing the risk of cardiac interventions based on gdf-15
HK1136627B (en) Means and methods for assessing the risk of cardiac interventions based on gdf-15
HK1229887B (en) Means and methods for assessing the risk of cardiac interventions based on gdf-15

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110420